Abstract: The present invention relates to the use of cannabinoids in the treatment of a neurodegenerative disease or disorder. In particular the cannabinoids cannabidiolic acid (CBDA) and cannabidivarin (CBDV) were able to produce neuroprotective effects in a mouse model of neurodegenerative disease. In particular these effects were associated with the symptoms associated with amyotrophic lateral sclerosis (ALS). Furthermore, the combination of the cannabinoid tetrahydrocannabinol (THC) with the drug olexisome provided a synergistic disease modifying effect in a mouse model of neurodegenerative disease. In particular these effects were associated with the symptoms associated with ALS.

Abstract: This technology relates to providing a web-based digital claims platform to provide users with a simple and customized experience when filing insurance claims. The platform is enabled by a plurality of back-end application programming interface (API) resources. These API resources are event-driven (e.g., when an “event” associated with the claim occurs, the status of the claim changes and the API is provided with updated information indicative of the change). The platform includes a customized user interface (UI) that tailors the claim experience to a particular user's needs. The customization can be based off of stated user preferences and/or learned user preferences associated with the user's past behavior. A user can perform/request various services through the customized UI's self-service function (e.g., rent a car, find a hotel room, select a repair shop, etc.). Additionally, the customized UI can enable the user upload documents, track claim status, find relevant help topics, etc.

Abstract: The present invention relates to topical pharmaceutical microemulsions of cyclosporine Acomprising a half (C-C 4) alkyl esters of poly (methyl vinyl ether-co-maleic anhydride) (PVM/MA) copolymers. The invention also relates to a process for the preparation of said compositions and to their use in the prevention and/or treatment of several diseases, particularly psoriasis and atopic dermatitis.

Abstract: The invention provides pharmaceutical stable semisolid topical compositions comprising between 0.2 to 5% of a des-fluoroquinolone compound, and a suitable carrier to manufacture an ointment or a cream.

Abstract: The present invention is related to a combination comprising a COX inhibitor, a Mg2+ source, and ascorbic acid or a stereoisomer or a pharmaceutically acceptable salt thereof, uses and pharmaceutical composition thereof.

Abstract: The invention provides pharmaceutical stable semisolid topical compositions comprising between 0.2 to 5% of a des-fluoroquinolone compound, and a suitable carrier to manufacture an ointment or a cream.

Abstract: The invention provides pharmaceutical stable semisolid topical compositions comprising between 0.2 to 5% of a des-fluoroquinolone compound, and a suitable carrier to manufacture an ointment or a cream.

Abstract: The invention provides pharmaceutical stable semisolid topical compositions comprising between 0.2 to 5% of a des-fluoroquinolone compound, and a suitable carrier to manufacture an ointment or a cream.

Abstract: The invention provides pharmaceutical stable semisolid topical compositions comprising between 0.2 to 5% of a des-fluoroquinolone compound, and a suitable carrier to manufacture an ointment or a cream.

Abstract: The invention provides pharmaceutical stable semisolid topical compositions comprising between 0.2 to 5% of a des-fluoroquinolone compound, and a suitable carrier to manufacture an ointment or a cream.

Abstract: The invention provides pharmaceutical stable semisolid topical compositions comprising between 0.2 to 5% of a des-fluoroquinolone compound, and a suitable carrier to manufacture an ointment or a cream.

Abstract: A process for regenerating spent clay which includes: (1) an extraction stage wherein an organic solvent or mixture of organic solvents are thoroughly mixed with the spent clay thus separating the entrained oil from the spent clay, (2) a reactivation stage wherein the oil-free spent clay is treated with acid, and (3) a thermal polishing step wherein the acid-treated, solvent-extracted spent clay is heated at a high temperature from about 500 degrees F to about 1400 degrees F for approximately one minute to five hours, preferably 10 minutes to 4 hours.

Abstract: A process for significantly decreasing processing time, reducing capital costs, increasing yield, improving quality, and improving the safety of refining petroleum residues and sludges generated by the oil producers, refineries and re-refiners comprising the steps of heating under vacuum the petroleum residues and sludges with steam or inert gas injection or both until a temperature ranging from between 680.degree. F. to 1000.degree. F. is attained and holding the mixture at this temperature for a short residence time of from less than an hour to abut 6 hours while vacuum and sparging are being carried out to generate asphalt. Volatile products are condensed to produce fuel, waxy oil and can be further processed to produce refined fuel, wax and dewaxed oil.

Abstract: A process for significantly decreasing the acid sludge settling time in waste oil recovery processes comprising the steps of heating used oil to a high temperature above 725 degrees Fahrenheit, cooling the heated oil, adding an oxidizing agent to the oil, allowing the acid sludge to settle within a period of approximately 24 to 72 hours, separating the acid-sludge-free oil from the acid sludge which settles out of solution as a result of addition of the oxidizing agent, and adding a polishing agent and separating the re-refined oil from the spent polishing agent. The spent polishing agent is recycled, and the acid sludge which settles out after oxidation is converted to either hard, oxidized asphalt or soft asphalt or asphalt products such as emulsions etc. The process produces a high quality re-refined oil rapidly and economically with no acid sludge disposal problem.